Ecovia Bio today announced the closing of a Series B funding round led by Pointe Angels, an independent angel investor group based in the Grosse Pointe communities east of Detroit, Michigan. The funding will support significant expansion of manufacturing capacity at Ecovia Bio's state-of-the-art Livonia facility to meet surging global demand for its AzuraBase and AzuraGel families of gamma polyglutamic acid (γ-PGA) and specialty biopolymer products across cosmetics, personal care, agriculture, and hygiene applications..

Ecovia Bio今天宣布，由Pointe Angels领投的B轮融资圆满结束。Pointe Angels是一家独立的天使投资者团体，位于密歇根州底特律东部的格罗斯波因特社区。此次融资将用于大幅扩大Ecovia Bio位于利沃尼亚的先进设施的生产能力，以满足其AzuraBase和AzuraGel系列γ-聚谷氨酸（γ-PGA）及相关特种生物聚合物产品在全球化妆品、个人护理、农业和卫生应用领域中激增的需求。

Ecovia Bio is a Michigan-based biotechnology company, a spinout from the University of Michigan, focused on the development and commercialization of sustainable, high-performance biopolymers derived from fermentation processes. The company's lead technology is based on gamma polyglutamic acid (γ-PGA), a natural biodegradable polymer with applications across multiple industries..

Ecovia Bio是一家总部位于密歇根州的生物技术公司，是从密歇根大学分拆出来的，专注于通过发酵工艺开发和商业化可持续、高性能的生物聚合物。该公司的核心技术基于γ-聚谷氨酸（γ-PGA），这是一种天然可降解的聚合物，在多个行业中具有应用价值。